↓ Skip to main content

Cochrane Database of Systematic Reviews

Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer

Overview of attention for article published in Cochrane database of systematic reviews, August 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
2 policy sources
twitter
8 X users
facebook
3 Facebook pages

Citations

dimensions_citation
81 Dimensions

Readers on

mendeley
123 Mendeley
Title
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
Published in
Cochrane database of systematic reviews, August 2013
DOI 10.1002/14651858.cd009256.pub2
Pubmed ID
Authors

Tiago B de Castria, Edina MK da Silva, Aecio FT Gois, Rachel Riera

Abstract

An estimated 220,000 new cases of non-small cell lung cancer (NSCLC) and 160,000 deaths are expected to occur in the US in 2013, representing about 28% of cancer-related mortality. Approximately 75% of these people will have locally advanced or metastatic disease and will be treated in a palliative setting. Platinum-based combination chemotherapy has benefits in terms of survival and symptom control when compared with best supportive care.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
United States 1 <1%
Unknown 121 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 16%
Student > Ph. D. Student 17 14%
Researcher 13 11%
Student > Bachelor 12 10%
Other 12 10%
Other 24 20%
Unknown 25 20%
Readers by discipline Count As %
Medicine and Dentistry 55 45%
Nursing and Health Professions 11 9%
Biochemistry, Genetics and Molecular Biology 6 5%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Economics, Econometrics and Finance 3 2%
Other 13 11%
Unknown 29 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2022.
All research outputs
#3,268,308
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#5,893
of 11,499 outputs
Outputs of similar age
#25,428
of 194,596 outputs
Outputs of similar age from Cochrane database of systematic reviews
#124
of 224 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,596 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 224 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.